Weight-loss drugs are driving a fivefold surge in whey protein prices, with the cost of some concentrates jumping from £4,302 per tonne in June 2023 to £23,751 in June 2024, according to data from the commodity intelligence platform Vesper. Food-grade whey powder across north-west Europe has hit a record high of approximately €1,700 (£1,469) per tonne, an increase of more than 50% since the start of the year, DCA Market Intelligence reports.
The GLP-1 link: why protein is now essential
The root cause lies in the exploding popularity of GLP-1 medications, initially developed for type-2 diabetes but now widely prescribed for weight management. Drugs such as Mounjaro work by significantly reducing appetite and slowing digestion, leading to a 20% reduction in daily calorie intake for users. While this drives rapid weight loss, a critical side effect is the loss of lean muscle mass. Health professionals therefore advise patients taking GLP-1 drugs to increase their protein consumption to preserve muscle while shedding fat. Whey protein – derived from milk during cheese-making and containing all nine essential amino acids – is particularly favoured because of its high bioavailability and ease of absorption. The combined effect of rising GLP-1 use, which an estimated 10-15% of the US population now relies on, and broader health advice emphasising protein, has created a surge in demand that the dairy industry is struggling to meet.
Market pressure: sold-out suppliers and struggling small businesses
The supply chain is under severe strain. According to the US Department of Agriculture’s dairy market news, the whey protein market is tightening, especially for whey protein concentrate (WPC) 34%, a commercial ingredient containing approximately 34% protein. Prices for WPC 34% are rising across the board, with the strongest increases at the top end. Some suppliers are already sold out for the rest of 2026, indicating significant pressure on inventories. One manufacturer is expected to stop producing WPC 34% after the summer, a move that market participants believe will further reduce availability. Highly concentrated whey protein (80% concentrate) has seen prices surge by up to 105% in the past year in the EU, reaching €22,000 per ton in early May 2026.
Small businesses are feeling the pinch acutely. Erika Tamayo, founder of the UK-based protein brand Hermosa, which sources grass-fed whey from farmers in Ireland and the Lake District, told us that ingredient costs have doubled quarter-on-quarter. “On the last two years, we’ve noticed every quarter the price is soaring up. We are managing to source protein, but we’re buying it at double the cost compared to last quarter,” she said. “We are now all fighting for stock allocation. Some of the bigger companies have absorbed all the price increases as they’re all trying to get market share and grow their businesses. Bigger players have more possibilities, so they don’t have to compromise. For a small business with a small range of products, it is harder.” She added that the GLP-1 boom has changed consumer habits: “Once GLP-1s started soaring, people realised how important protein is in their diet. Then loads of products in mainstream supermarkets started adding whey protein to everything – popcorn, crisps, even protein doughnuts. Everything now has protein in it.”
Industry responses: new plants, blends and alternatives
Jasper Endlich, an analyst at Vesper, acknowledged the market is under pressure but noted signs of adaptation. “If you look at overall supply and demand, the market is still finding a home for the product, but there’s clearly a shortage in the sense that people want more than there physically is available. Manufacturers would like to produce more and build safety stocks, but they haven’t been able to do that,” he said. The good news, he added, is that new production plants are opening. Meanwhile, some companies are reformulating products to manage costs. “Where products may once have contained only whey protein, some are now using blends with a small amount of milk protein mixed in. The overall protein content remains broadly similar, but the ingredient cost can be half or even a third of the price. There are ways for companies to manage the pressure while supply catches up.”
Beyond whey, alternatives are being explored. Beef protein isolate, collagen, egg white protein, and vegan options such as hemp, pea, brown rice and soy proteins are gaining traction. A growing trend is the development of “GLP-1 friendly” foods and supplements – high in protein, fibre and essential nutrients, often in portion-controlled formats. Companies like Nestlé, with its Vital Pursuit line, and Abbott Laboratories are already launching products specifically for GLP-1 users. Experimental drugs are also in development that aim to preserve lean mass in people taking these medications.
The traditional dairy model – where whey was a by-product of cheese production – has been turned on its head. In the US, industry observers describe a “tail wagging the dog” phenomenon, with whey now more valuable than cheese and processors prioritising whey output. The UK whey protein market, valued at roughly $59 million in 2022, is projected to grow substantially, with forecasts ranging from $92.77 million by 2031 to over $1.2 billion by 2033, depending on the methodology. But for now, small businesses like Erika Tamayo’s Hermosa face a daily struggle: “The challenge is managing lead times and availability. Every quarter we have to wait and see how much supply is available, while also buying months in advance to make sure we don’t run out of stock.”